ArticleBlood2023
How I treat AML incorporating the updated classifications and guidelines.
Article in Blood, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prediction models for different types of leukemia: a systematic review and critical appraisal.Journal of cancer research and clinical oncology · 2025Pooled it
- A Markov analysis of azacitidine and venetoclax vs induction chemotherapy for medically fit patients with AML.Blood advances · 2024Pooled it
- Targeted Therapies Combined with Intensive Chemotherapy in Fit Acute Myeloid Leukemia: Past Developments, Current Evidence, and Future Therapeutic Paradigms.Journal of clinical medicine · 2026Review
- A Novel Potent and Selective GCN2 Inhibitor, APL-4098, Has Antileukemic Activity through Dysregulation of Mitochondrial Function.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Landscape of Measurable Residual Disease in Acute Myeloid Leukemia: From Molecular Detection to Clinical Practice.Medical sciences (Basel, Switzerland) · 2026Review
- The global epidemiology of acute myeloid leukaemia.Nature reviews. Clinical oncology · 2026Review
- The ER Stress-related Gene Prognostic Signature for Predicting Chemosensitivity and Prognosis in AML.Recent patents on anti-cancer drug discovery · 2026Article
- Prediction model for survival outcome in patients with acute myeloid leukemia: a multicenter prospective cohort study from Thai Acute Leukemia Working Group.Frontiers in oncology · 2026Article
- TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a comprehensive overview of targeted approaches.Frontiers in oncology · 2026Review
- Article
- MicroRNA-142 improves IL1RAP CAR-T cell activity in acute myeloid leukemia.Journal of hematology & oncology · 2025Article
- Hypochlorous Acid-Gated Hydrolysis of a Phosphinate Ester Dye in Living Cells.Journal of the American Chemical Society · 2025Article
- Article
- Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia.Bone marrow transplantation · 2025Article
- Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia.Bone marrow transplantation · 2025Article
- T-cell immune cluster analysis using CyTOF identifies unique subgroups of patients with acute myeloid leukemia.Blood advances · 2025Article
- Gene Signature-Based Prognostic Model for Acute Myeloid Leukemia: The Role ofInternational journal of medical sciences · 2025Article
- Prognostic impact of methylation-related gene mutations in elderly acute myeloid leukemia: a real-world retrospective analysis.Frontiers in medicine · 2025Article
- Targeting SLFN11-regulated pathways restores chemotherapy sensitivity in AML.Blood neoplasia · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The European LeukemiaNet recently revised both the clinical (2022) and measurable residual disease testing (2021) guidelines for acute myeloid leukemia (AML). The updated World Health Organization and International Consensus Classification for myeloid neoplasms were also published in 2022. Together, these documents update the classification, risk stratification, prognostication, monitoring recommendations, and response assessment of patients with AML. Increased appreciation of the genetic drivers of AML over the past decade and our increasingly sophisticated understanding of AML biology have been translated into novel therapies and more complex clinical treatment guidelines. Somatic genetic abnormalities and germ line predispositions now define and guide treatment and counseling for the subtypes of this hematologic malignancy. In this How I Treat article, we discuss how we approach AML in daily clinical practice, considering the recent updates in the context of new treatments and discoveries over the past decade.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.